Humacyte Set to Go Public, Raise $175 Million from Top-tier Investors
Durham-based Humacyte, a regenerative medicine company that received start-up support from the North Carolina Biotechnology Center 15 years ago, is going public in a novel deal that will give it a market capitalization of $1.1 billion.
Humacyte and Alpha Healthcare Acquisition Corp., a special purpose acquisition company (SPAC) based in New York, have signed a business-combination agreement to take Humacyte public, along with a $175M PIPE financing agreement.
“We are very pleased to have support from top-tier investors and access to the U.S. capital markets following the closing of this proposed transaction, which will leave Humacyte well-capitalized to provide first-in-class therapies to treat several life-threatening diseases,” Laura Niklason, M.D., Ph.D., founder and chief executive officer of Humacyte, said in a prepared statement.
Boston biotech Ensoma lands $70m in funding, partnership with Takeda
By Anissa Gardizy Globe Staff,Updated February 11, 2021, 7:00 a.m.
Email to a Friend
Thereâs no shortage of local
biotechs working in the field of genomic medicine, but something still keeps investor Kush Parmar up at night: The managing partner at Boston venture capital firm 5AM Ventures knows the emerging treatments
wonât be widely accessible to patients.
Some forms of gene therapy and gene editing require a patientâs cells to be removed and reinserted into the body. Others involve cell donors, or initial steps such as chemotherapy â treatments that can only be done in specialized centers or that require days of hospitalization.
Fred Hutch, Univ. of Washington biotech spinout Ensoma launches with $70M in funding
February 11, 2021 at 9:15 am
Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center. (Fred Hutch Photo)
New spinout: Boston-based biotech startup Ensoma launched Thursday and announced a $70 million Series A funding round. The company is built on technology developed over two decades by Seattle researchers Dr. Hans-Peter Kiem of the Fred Hutchinson Cancer Research Center and Dr. André Lieber of the University of Washington School of Medicine.
The company will be based in Boston because the city “is the epicenter of biotech and Ensoma could quickly draw the talent, not only for research but as the company scales in manufacturing and clinical development,” said Paula Soteropoulos, the company’s executive chairman. The company’s lead investor and top leadership are also in Boston.
Press release content from Business Wire. The AP news staff was not involved in its creation.
MOMA Therapeutics Appoints Asit Parikh, M.D., Ph.D. as President and Chief Executive Officer
February 1, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 1, 2021
MOMA Therapeutics, a biopharmaceutical company discovering the next generation of precision medicines by targeting molecular machines that underlie human disease, today announced that Asit Parikh, M.D., Ph.D., has been appointed as the company’s president and chief executive officer, effective April 5, 2021. Dr. Parikh brings more than 20 years of academic and industry experience to MOMA. He will succeed interim founding CEO, Reid Huber, Ph.D., a partner at Third Rock Ventures, who will remain on MOMA’s Board of Directors.
AltPep Raises $23M Jumpstarting Work on Alzheimer s Disease
Search jobs SEATTLE - January 14, 2021 - (Newswire.com)
AltPep Corporation, a privately held biomedical company focused on diagnosing and treating Central Nervous System amyloid disorders, starting with Alzheimer s Disease, today announced it closed a $23.150 million Series A investment round. Matrix Capital Management led the investment, with significant participation by Alexandria Venture Investments. In conjunction with the financing, David Goel, Managing General Partner and Founder of Matrix Capital Management and Joel Marcus, Executive Chairman and Founder of Alexandria Real Estate Equities/Alexandria Venture Investments, have joined the AltPep Board of Directors.
The proceeds of the Series A investment will be used to advance a breakthrough technology developed at the University of Washington laboratory of AltPep Founder and CEO, Valerie Daggett, Ph.D., that targets the misfolded forms of amyloi